BMPR1a-Fc has previously been shown to increase bone volume in a murine model of osteoporosis26, but has never been investigated within the tumour–bone environment and represents a complementary approach to target the BMP pathway in myeloma bone disease in vivo. Here, BMPR1A is linked to plasma cell myeloma.